



Universiteit
Leiden
The Netherlands

Viral gene therapy approaches for CRB1 retinal disease

Boon, N.

Citation

Boon, N. (2023, November 2). *Viral gene therapy approaches for CRB1 retinal disease*. Retrieved from <https://hdl.handle.net/1887/3655975>

Version: Publisher's Version

License: [Licence agreement concerning inclusion of doctoral thesis in the Institutional Repository of the University of Leiden](#)

Downloaded from: <https://hdl.handle.net/1887/3655975>

Note: To cite this publication please use the final published version (if applicable).

Viral Gene Therapy Approaches for *CRB1* Retinal Disease

Nanda Boon

ISBN 978-94-6483-429-1

Cover Art Nanda Boon & Hugo Veldhuizen.

Printed by Ridderprint, Alblasserdam.

The printing of this thesis was financially supported by Stichting Blindenhulp.

Copyright © Nanda Boon, 2023.

All rights are reserved. No part of this publication may be reproduced, stored or transmitted in any form or by any means without permission of the copyright owners.

Viral gene therapy approaches for *CRB1* retinal disease

Proefschrift

ter verkrijging van
de graad van doctor aan de Universiteit Leiden,
op gezag van rector magnificus prof.dr.ir. H. Bijl,
volgens besluit van het college voor promoties
te verdedigen op donderdag 2 november 2023
klokke 12:30 uur

door

Nanda Boon
geboren te Vught,
in 1994

Promotor: Prof. Dr. G.P.M. Luyten

Co-Promotor: Dr. J. Wijnholds

Leden promotiecommissie:

Prof. Dr. R.C. Hoeben

Prof. Dr. W.M.C. van Roon-Mom

Prof. Dr. C.J.F. Boon, LUMC and Amsterdam UMC

Prof. Dr. J. Verhaagen, Netherlands Institute for Neuroscience

Prof. Dr. A.A.B. Bergen, Amsterdam UMC

The research here described was conducted at the Department of Ophthalmology, at the Leiden University Medical Center (LUMC). The studies described in this thesis were financially supported by Foundation Fighting Blindness, The Netherlands Organization for Health Research and Development (ZonMw), Stichting Blinden-penning, Leiden Regenerative Medicine Platform, Rotterdamse Stichting Blindenbelangen, Landelijke Stichting voor Blinden en Slechtienden, Dutch blindness funds (Uitzicht), MaculaFonds, Stichting Blindenhulp, University of Pennsylvania Orphan Disease Center in partnership with Curing Retinal Blindness Foundation, Bontius Stichting, and HORAMA (now known as Coave Therapeutics).

Table of Contents

Chapter 1	General Introduction	
	1.1 Research Models and Gene Augmentation Therapy for <i>CRB1</i> Retinal Dystrophies	8
	1.2 Aims and Outline of this Thesis	
Chapter 2	CRB2 Loss in Rod Photoreceptors is Associated with Progressive Loss of Retinal Contrast Sensitivity	42
Chapter 3	Defining Phenotype, Tropism, and Retinal Gene Therapy Using Adeno-Associated Viral Vectors (AAVs) in New-Born Brown Norway Rats with a Spontaneous Mutation in <i>Crb1</i>	84
Chapter 4	AAV-Mediated Gene Augmentation Therapy of <i>CRB1</i>-Patient Derived Retinal Organoids Restores the Histological and Transcriptional Retinal Phenotype	130
Chapter 5	Characterization and AAV-Mediated Gene Therapy in Human <i>CRB1</i>^{KO} and <i>CRB1</i>^{KO}<i>CRB2</i>^{+/-} Retinal Organoids	176
Chapter 6	General Discussion	212
Chapter 7	Summary; Nederlandse Samenvatting; List of publications; Curriculum Vitae; Acknowledgements	238
